Profile data is unavailable for this security.
About the company
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
- Revenue in USD (TTM)0.00
- Net income in USD-18.21m
- Incorporated2014
- Employees14.00
- LocationImmix Biopharma Inc11400 West Olympic Blvd., Suite 200LOS ANGELES 90064United StatesUSA
- Phone+1 (310) 651-8041
- Websitehttps://immixbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Odonate Inc | 0.00 | -102.07m | 50.02m | 137.00 | -- | 1,844.41 | -- | -- | -13.59 | -13.59 | 0.00 | 9.27 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
Turnstone Biologics Corp | 0.00 | -74.92m | 52.04m | 82.00 | -- | 0.6504 | -- | -- | -3.53 | -3.53 | 0.00 | 3.46 | 0.00 | -- | -- | 0.00 | -80.25 | -- | -94.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
Rockwell Medical Inc | 86.62m | -8.42m | 53.60m | 237.00 | -- | 2.53 | -- | 0.6188 | -0.3584 | -0.3584 | 3.33 | 0.6984 | 1.90 | 13.28 | 10.12 | 365,485.20 | -18.47 | -46.29 | -27.53 | -65.38 | 10.59 | 4.66 | -9.72 | -36.51 | 1.38 | -3.54 | 0.331 | -- | 14.84 | 5.69 | 54.82 | -- | 76.21 | -- |
CEL-SCI Corp | 0.00 | -29.95m | 59.58m | 43.00 | -- | 4.16 | -- | -- | -0.6304 | -0.6304 | 0.00 | 0.2645 | 0.00 | -- | -- | -- | -87.78 | -70.19 | -103.56 | -78.31 | -- | -- | -- | -15,434.15 | 1.18 | -39.26 | 0.4319 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
Gritstone bio Inc | 15.65m | -144.89m | 62.04m | 231.00 | -- | 4.01 | -- | 3.97 | -1.57 | -1.57 | 0.17 | 0.1423 | 0.0901 | -- | 40.53 | 67,727.27 | -83.47 | -48.08 | -97.70 | -55.18 | -- | -- | -926.13 | -573.71 | -- | -554.88 | 0.7428 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
Immix Biopharma Inc | 0.00 | -18.21m | 64.72m | 14.00 | -- | 2.32 | -- | -- | -0.9263 | -0.9263 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -77.50 | -- | -90.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
Marinus Pharmaceuticals Inc | 28.29m | -145.34m | 66.47m | 165.00 | -- | -- | -- | 2.35 | -2.64 | -2.64 | 0.5142 | -0.2992 | 0.1554 | 0.8536 | 3.72 | 171,442.40 | -79.82 | -49.64 | -96.93 | -57.76 | 91.22 | -- | -513.80 | -518.96 | 2.93 | -13.62 | 1.29 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
CASI Pharmaceuticals Inc | 28.94m | -30.48m | 70.36m | 176.00 | -- | 4.55 | -- | 2.43 | -2.28 | -2.28 | 2.16 | 1.15 | 0.3954 | 1.00 | 3.41 | 164,437.50 | -40.88 | -34.75 | -59.15 | -46.91 | 58.36 | 55.98 | -103.40 | -153.72 | 3.25 | -76.70 | 0.5458 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 71.43m | 134.00 | 6.04 | 0.2858 | 2.19 | 0.2773 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
China Health Industries Holdings, Inc. | 95.95k | -1.36m | 72.09m | 32.00 | -- | -- | -- | 751.37 | -0.0208 | -0.0208 | 0.0015 | -0.0366 | 0.0037 | 0.5035 | 20.57 | 2,998.44 | -5.18 | 3.04 | -6.89 | 3.66 | -5.34 | 69.55 | -1,419.49 | 28.61 | 0.0377 | -- | 1.76 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
Journey Medical Corp | 80.00m | -4.16m | 72.17m | 58.00 | -- | 7.93 | -- | 0.9021 | -0.3095 | -0.3095 | 4.13 | 0.6498 | 0.985 | 2.27 | 4.28 | 1,379,276.00 | -5.12 | -- | -17.85 | -- | 66.22 | -- | -5.20 | -- | 0.9357 | 0.4049 | 0.5773 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
SCYNEXIS Inc | 140.39m | 101.33m | 73.29m | 29.00 | 0.9642 | 0.989 | -- | 0.5221 | 2.01 | 2.01 | 2.89 | 1.96 | 1.49 | -- | 136.30 | 4,840,862.00 | 107.48 | -30.02 | 175.37 | -36.35 | 88.97 | -- | 72.18 | -86.76 | -- | 193.81 | 0.1433 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
Universe Pharmaceuticals Inc | 32.31m | -6.16m | 74.25m | 225.00 | -- | 0.2879 | -- | 2.30 | -1.70 | -1.70 | 8.91 | 10.91 | 0.5727 | 7.93 | 2.50 | 143,594.40 | -10.92 | 5.31 | -14.34 | 7.07 | 31.93 | 46.26 | -19.08 | 6.25 | 2.43 | -28.05 | 0.1218 | 0.00 | -19.52 | 2.53 | 29.46 | -- | -21.17 | -- |
Assembly Biosciences Inc | 12.95m | -51.36m | 74.32m | 65.00 | -- | 2.04 | -- | 5.74 | -11.22 | -11.22 | 2.76 | 5.95 | 0.1276 | -- | 34.07 | 199,200.00 | -50.60 | -39.69 | -66.58 | -44.03 | -- | -- | -396.63 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
LifeVantage Corp | 205.45m | 3.60m | 76.08m | 248.00 | 21.42 | 2.84 | 10.46 | 0.3703 | 0.2796 | 0.2796 | 16.01 | 2.11 | 3.20 | 2.53 | 91.56 | 828,443.60 | 5.60 | 11.65 | 8.51 | 18.92 | 79.32 | 82.20 | 1.75 | 3.42 | 1.01 | -- | 0.00 | 5.23 | 3.41 | 0.9838 | -18.59 | -18.77 | -7.98 | -- |
Holder | Shares | % Held |
---|---|---|
AIGH Capital Management LLCas of 31 Mar 2024 | 1.56m | 5.89% |
Bleichroeder LPas of 31 Mar 2024 | 850.00k | 3.22% |
Cable Car Capital LLCas of 31 Mar 2024 | 670.46k | 2.54% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 456.19k | 1.73% |
Lynwood Capital Management, Inc.as of 31 Mar 2024 | 405.00k | 1.53% |
Renaissance Technologies LLCas of 31 Mar 2024 | 265.50k | 1.01% |
Geode Capital Management LLCas of 31 Mar 2024 | 124.77k | 0.47% |
Private Advisor Group LLCas of 31 Mar 2024 | 98.78k | 0.37% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 76.90k | 0.29% |
Corsair Capital Management LPas of 31 Mar 2024 | 69.39k | 0.26% |